Clinical effect of anti-vascular endothelial growth factor on retinopathy of premature infants in different regions

ZHANG Binyu; YANG Zhiwei

doi:10.7619/jcmp.201913023

Journal of Clinical Medicine in Practice > 2019 > 23(13): 82-84, 88. > DOI: 10.7619/jcmp.201913023

ZHANG Binyu, YANG Zhiwei. Clinical effect of anti-vascular endothelial growth factor on retinopathy of premature infants in different regions[J]. Journal of Clinical Medicine in Practice, 2019, 23(13): 82-84, 88. DOI: 10.7619/jcmp.201913023

Citation:

PDF (659 KB)

Clinical effect of anti-vascular endothelial growth factor on retinopathy of premature infants in different regions

ZHANG Binyu¹,
YANG Zhiwei²

1.
Department of Neonatology, Ankang Maternal and Child Health Hospital in ShaanxiProvince, Ankang, Shaanxi, 725000
2.
Department of Ophthalmology, Yulin Xuyong Eye Hospital in Shaanxi Province, Yulin, Shaanxi, 719000

More Information

Received Date: April 19, 2019
Accepted Date: June 05, 2019
Available Online: February 23, 2021
Published Date: July 14, 2019

Graphical Abstract

Abstract

Abstract

Objective To investigate the clinical effect of anti-vascular endothelial growth factor (VEGF) in the treatment of retinopathy of premature infants in different regions.
Methods Clinical data of 200 premature infants with retinopathy in our hospital were retrospectively analyzed, and these patients were divided into group A (Ⅰ district, 125 cases with 232 eyes) and group B (Ⅱ district, 75 cases with 138 eyes) according to the lesion areas. The clinical efficacy was compared after anti-VEGF treatment.
Results The response rates of initial treatment, and secondary treatment of group A were 64.66%, 71.95%, respectively, which were lower than 75.36%, 94.12%, respectively, in group B (P < 0.05). The incidence of complications was 4.00% in group A and 2.67% in group B, but no significant difference was seen between two groups(P>0.05).
Conclusion VEGF treatment for premature infants with retinopathy in Ⅰ, Ⅱ lesions is safe in treatment and has better curative efficacy, but therapeutic efficacy in area Ⅰ is lower.
- premature infants with retinopathy,
- lesions,
- anti-vascular endothelial growth factor,
- ranibizumab

FullText(HTML)

References (18)

References

[1]	李丹, 董宇. 早产儿视网膜病变发病基础及抗VEGF药物治疗研究进展[J]. 眼科新进展, 2016, 36(4): 396-400. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ201604026.htm
[2]	王群, 白华, 赵杰, 等. 新型VEGF靶向抗体眼局部应用的安全性评价[J]. 国际眼科杂志, 2017, 17(11): 2019-2023. doi: 10.3980/j.issn.1672-5123.2017.11.07
[3]	中国医师协会新生儿科医师分会. 早产儿治疗用氧和视网膜病变防治指南(修订版)[J]. 2013, 28(23): 1835-1836.
[4]	杨秀梅, 何涛, 邱岩, 等. 玻璃体内注射雷珠单抗治疗早产儿视网膜病变疗效观察[J]. 眼科新进展, 2017, 37(2): 137-140. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ201702011.htm
[5]	李玉, 薛黎萍. 早产儿视网膜病变危险因素研究进展[J]. 国际眼科杂志, 2017, 17(7): 1265-1267. https://www.cnki.com.cn/Article/CJFDTOTAL-GJYK201707019.htm
[6]	王倩, 李聪慧, 信伟, 等. 早产儿视网膜病变2203例筛查结果分析[J]. 国际眼科杂志, 2018, 18(6): 1093-1096. https://www.cnki.com.cn/Article/CJFDTOTAL-GJYK201806029.htm
[7]	郭佃强, 韩梅, 单若冰, 等. 多胎与单胎早产儿视网膜病变的发病率及危险因素的比较[J]. 眼科新进展, 2017, 37(4): 348-350. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ201704014.htm
[8]	朱赟, 潘家华. 172例早产儿视网膜病变高危因素分析[J]. 安徽医学, 2017, 38(8): 976-978. doi: 10.3969/j.issn.1000-0399.2017.08.006
[9]	张建军. 早产儿视网膜病变筛查结果及高危因素分析[J]. 中国妇幼保健, 2017, 32(19): 4707-4709. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201719038.htm
[10]	童林利, 熊永强, 林春堤, 等. 新生儿眼底疾病筛查结果及早产儿视网膜病变高危因素分析[J]. 中国妇幼保健, 2018, 33(18): 4262-4265. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201818057.htm
[11]	雷朝霞, 唐剑波, 娄志武, 等. 湖州地区784例早产儿视网膜病变的筛查结果与分析[J]. 中国儿童保健杂志, 2017, 25(11): 1169-1172. https://www.cnki.com.cn/Article/CJFDTOTAL-ERTO201711025.htm
[12]	徐蕊, 孙智慧, 刘颖, 等. 激光光凝对早产儿视网膜病变阈值前Ⅰ型的作用分析[J]. 陕西医学杂志, 2018, 47(1): 66-68. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYZ201801022.htm
[13]	田汝银, 张国明, 程璐璐, 等. 早产儿视网膜病变激光术后嵴前无血管区的临床观察[J]. 国际眼科杂志, 2017, 17(4): 778-780. https://www.cnki.com.cn/Article/CJFDTOTAL-GJYK201704055.htm
[14]	程莉萍, 董建英, 李秋平, 等. 床旁玻璃体腔注射抗VEGF治疗早产儿视网膜病的围术期护理[J]. 中华现代护理杂志, 2016, 22(12): 1698-1700. doi: 10.3760/cma.j.issn.1674-2907.2016.12.017
[15]	王改琴, 高雪辉. 早产儿视网膜病变玻璃腔内注射雷珠单抗对患儿VEGF、IGF-1、GLU的影响[J]. 西北国防医学杂志, 2017, 38(6): 356-360. https://www.cnki.com.cn/Article/CJFDTOTAL-XBGY201706002.htm
[16]	侯宝杰, 赵杰, 徐青. 抗血管内皮生长因子药种类及其眼科应用[J]. 武警医学, 2017, 28(4): 325-328. doi: 10.3969/j.issn.1004-3594.2017.04.001
[17]	卢跃兵, 黄云云, 孙先桃, 等. 抗血管内皮生长因子玻璃体内注射治疗不同区域早产儿视网膜病变的疗效观察[J]. 眼科新进展, 2017, 37(5): 477-479. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ201705021.htm
[18]	胡志强, 张伶俐, 李佳莲, 等. 血管内皮生长因子抑制剂治疗早产儿视网膜病变有效性和安全性的Meta分析[J]. 中国药房, 2016, 27(24): 3377-3379. doi: 10.6039/j.issn.1001-0408.2016.24.21

Cited By

Get Citation

PDF

XML

Article views PDF downloads

Turn off MathJax

Article Contents

Abstract

References

Clinical effect of anti-vascular endothelial growth factor on retinopathy of premature infants in different regions

Abstract

References

Catalog

Export File

Citation

Format

Content